/

Empresas

An

No verificado

Anthos Therapeutics, Inc.

Sobre qué escribimos

CardiologíaEventosFarmacéuticaIndustriaSalud

1 Comunicados de prensa

Ver todos los comunicados de prensa

02/09/2024

Salud

Medicina - Varios

Ciencia

Farmacéutica

Cardiología

Eventos

Industria

Anthos Therapeutics Unveils Additional Analysis from the Landmark AZALEA-TIMI 71 Study Demonstrating that the Factor XI Inhibitor Abelacimab was Associated with Remarkably Low Levels of Periprocedural Bleeding in Patients with Atrial Fibrillation

Fuente

Anthos Therapeutics, Inc.

Editor

1.00

0

Seguidores

0

Compatibilidad

0